Cover Image
Market Research Report
Product code 
1084697

Fibromyalgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Published: | Coherent Market Insights | 176 Pages | Delivery time: 2-3 business days

Price

Back to Top
Fibromyalgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028
Published: May 3, 2022
Coherent Market Insights
Content info: 176 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Fibromyalgia, also called fibromyalgia syndrome, is a chronic neurologic disorder, which causes severe pain all over the body. The cause of fibromyalgia is unknown, however, it can be caused due to various factors, including genetics cause, physical or emotional trauma or due to infections. The symptoms related to fibromyalgia includes widespread pain, severe fatigue, sleep problems, cognitive difficulties, and others. Various medications such as antidepressant drugs, antiepileptic drugs, muscle relaxants, and analgesics are used for the management and treatment of fibromyalgia.

Market Dynamics

Key players in the market are focusing on frequent research and development activities for development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period. For instance, drug candidate IMC-1 is being developed by Innovative Med Concepts, which received fast track designation from the U.S. FDA in 2016

In December 2018, Aptinyx Inc. announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

In 2021, Innovative Med Concepts announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.

Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. have launched generic drugs for fibromyalgia treatment in the market.

Launch of generic versions of branded fibromyalgia drugs is expected to affect the revenue of branded drugs. However, it is expected to increase adoption and affordability of drugs and support fibromyalgia treatment market growth in the near future.

For instance, in December 2013, Sun Pharmaceutical Industries Ltd. announced that the U.S. FDA granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg, and 60 mg.

Key features of the study:

  • This report provides in-depth analysis of fibromyalgia treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global fibromyalgia treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the fibromyalgia treatment market

Detailed Segmentation:

  • Global Fibromyalgia Treatment Market, By Drug Class :
    • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
    • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
    • Muscle Relaxants
    • Analgesics
    • Others (Including Pipeline Drugs)
  • Global Fibromyalgia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Fibromyalgia Treatment Market, By Region:
    • North America
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • Central Africa
      • South Africa
      • North Africa
  • Company Profiles
    • Eli Lilly and Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Novartis AG
    • Allergan plc.
    • Sun Pharmaceutical Industries Ltd.
    • Aptinyx, Inc.
    • Prismic Pharmaceuticals, Inc.
    • Innovative Med Concepts, Inc.
    • Intec Pharma Ltd.
    • Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1691

Table of Contents

1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Patent Litigations
    • Reimbursement
    • Patent Landscape (ANDA/NDA Intelligence)
    • PEST Analysis
    • Porter's Analysis

4. Global Fibromyalgia Treatment Market, By Drug Class, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Segment Trends
    • Milnacipran (Savella and Other Generics)
    • Duloxetine (Cymbalta and Other Generics)
    • Others
    • Antiepileptics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Segment Trends
    • Pregabalin (Lyrica and Other Generics)
    • Others
    • Muscle Relaxants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Analgesics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others (Including Pipeline Drugs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global Fibromyalgia Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Fibromyalgia Treatment Market, By Region, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Aptinyx, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Prismic Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Innovative Med Concepts, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Intec Pharma Ltd
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Astellas Pharma Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact